X Facebook LinkedIn WhatsApp Press Releases Any 2024 2023 2022 2021 2020 2019 2018 (-) 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2017 May 18, 2017 argenx announces full exercise of underwriters’ option to purchase additional ADSs May 16, 2017 argenx raises approximately $100 million gross proceeds with NASDAQ IPO May 15, 2017 argenx announces size of initial public offering in the United States increased to 5 million ADSs May 7, 2017 argenx announces launch of proposed initial public offering in the United States May 7, 2017 argenx announces launch of proposed initial public offering in the United States May 3, 2017 argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis May 1, 2017 argenx reports first quarter 2017 financial results and provides business update April 25, 2017 argenx announces results of Annual General Meeting 2017 April 23, 2017 argenx files registration statement for a proposed public offering in the United States April 12, 2017 argenx receives first preclinical milestone payment in AbbVie collaboration April 11, 2017 argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients March 30, 2017 argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Next page Next › Last page Last »